PCSA — Processa Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $1.22m
- $0.04m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.72 | ||
| Price to Tang. Book | 0.72 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -710.15% | ||
| Return on Equity | -354.51% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. The three NGC treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri) and two non-oncology drug assets are PCS12852, and PCS499. NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil.PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan (SN-38). PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes.
Directors
- David Young CHM (68)
- Wendy Guy FDR (57)
- Sian Bigora FDR (61)
- James Stanker CFO (63)
- R. Michael Floyd COO (65)
- Patrick Lin OTH (56)
- Khalid Islam DRC (65)
- Geraldine Pannu IND (51)
- Virgil Thompson IND (82)
- Justin Yorke IND (55)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 29th, 2011
- Public Since
- October 7th, 2013
- No. of Shareholders
- 184
- No. of Employees
- 10
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 5,269,240
- Address
- 7380 Coca Cola Dr Ste 106, HANOVER, 21076-1789
- Web
- https://www.processapharmaceuticals.com/
- Phone
- +1 4437763133
- Auditors
- Cherry Bekaert LLP
Upcoming Events for PCSA
Processa Pharmaceuticals Inc Annual Shareholders Meeting
Processa Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2025 Processa Pharmaceuticals Inc Earnings Release
Q3 2025 Processa Pharmaceuticals Inc Earnings Release
Similar to PCSA
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Processa Pharmaceuticals share price?
As of Today at 22:45 UTC, shares in Processa Pharmaceuticals are trading at $0.23. This share price information is delayed by 15 minutes.
How has the Processa Pharmaceuticals share price performed this year?
Shares in Processa Pharmaceuticals last closed at $0.23 and the price had moved by -89.75% over the past 365 days. In terms of relative price strength the Processa Pharmaceuticals share price has underperformed the S&P500 Index by -90.76% over the past year.
What are the analyst and broker recommendations for Processa Pharmaceuticals?
The overall consensus recommendation for Processa Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Processa Pharmaceuticals dividend yield?
Processa Pharmaceuticals does not currently pay a dividend.
Does Processa Pharmaceuticals pay a dividend?
Processa Pharmaceuticals does not currently pay a dividend.
When does Processa Pharmaceuticals next pay dividends?
Processa Pharmaceuticals does not currently pay a dividend.
How do I buy Processa Pharmaceuticals shares?
To buy shares in Processa Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Processa Pharmaceuticals?
As of the previous close price of $0.23, shares in Processa Pharmaceuticals had a market capitalisation of $1.22m.
Where are Processa Pharmaceuticals shares listed?
Here are the trading details for Processa Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: PCSA
What kind of share is Processa Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Processa Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Processa Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Processa Pharmaceuticals is $6.00. That is 2490.67% above the last closing price of $0.23.
Analysts covering Processa Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$2.16 for the next financial year.
Find out moreWhat is the trend in the Processa Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Processa Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -79.77%.
As of the last closing price of $0.23, shares in Processa Pharmaceuticals were trading -76.26% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Processa Pharmaceuticals PE Ratio?
The Processa Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.23.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Processa Pharmaceuticals?
Processa Pharmaceuticals' management team is headed by:
- David Young - CHM
- Wendy Guy - FDR
- Sian Bigora - FDR
- James Stanker - CFO
- R. Michael Floyd - COO
- Patrick Lin - OTH
- Khalid Islam - DRC
- Geraldine Pannu - IND
- Virgil Thompson - IND
- Justin Yorke - IND